G1 Therapeutics Inc (GTHX.OQ)
39.26USD
11:53am EDT
$0.86 (+2.24%)
$38.40
$38.25
$39.37
$36.38
16,954
77,830
$41.90
$12.04
About
Overall
| Beta: | -- |
| Market Cap(Mil.): | $1,235.51 |
| Shares Outstanding(Mil.): | 31.79 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| GTHX.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 185.16 | 33.25 |
| EPS (TTM): | -2.40 | -- | -- |
| ROI: | -88.38 | -0.71 | 13.13 |
| ROE: | -456.98 | -2.76 | 14.96 |
BRIEF-G1 Therapeutics Files For Offering Of 3 Mln Shares
* FILES FOR OFFERING OF 3 MILLION SHARES OF ITS COMMON STOCK Source text: (http://bit.ly/2D2beLO) Further company coverage:
BRIEF-G1 Therapeutics Announces Positive Trilaciclib Phase 2A Topline Data Showing Robust Myelopreservation Benefits In Patients With Small Cell Lung Cancer
* G1 THERAPEUTICS ANNOUNCES POSITIVE TRILACICLIB PHASE 2A TOPLINE DATA SHOWING ROBUST MYELOPRESERVATION BENEFITS IN PATIENTS WITH SMALL CELL LUNG CANCER
BRIEF-G1 Therapeutics Qtrly Net Loss Per Share $0.60
* G1 THERAPEUTICS REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND RECENT OPERATIONAL HIGHLIGHTS
BRIEF-Medimmune Ventures Sells 133,906 Shares Of G1 Therapeutics Inc's Common Stock On Dec 1
* MEDIMMUNE VENTURES INC REPORTS SALE OF 133,906 SHARES OF G1 THERAPEUTICS INC'S COMMON STOCK ON DEC 1 AT $19.75 PER SHARE - SEC FILING Source text: (http://bit.ly/2iVgOvs) Further company coverage:
BRIEF-G1 Therapeutics And AstraZeneca Enter Clinical Trial Collaboration In Non-Small Cell Lung Cancer
* G1 THERAPEUTICS AND ASTRAZENECA ENTER CLINICAL TRIAL COLLABORATION IN NON-SMALL CELL LUNG CANCER
BRIEF-G1 Therapeutics Inc appoints Barclay (Buck) Phillips as CFO and SVP, corporate development
* G1 Therapeutics Inc - appoints barclay (buck) phillips as chief financial officer and senior vice president, corporate development
BRIEF-G1 Therapeutics qtrly loss per share $0.55
* G1 therapeutics reports third quarter 2017 financial results and recent operational highlights
Estimates